Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Thyroid Hormone Replacement After Hemithyroidectomy
2025-524175-23-00Phase 4Authorised
- Sponsor
- Central Denmark Region
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of levothyroxine sodium in hypothyroidism, chronic kidney disease (CKD) and nephropathy (2 arms), sponsored by Central Denmark Region. Primary endpoint: Change in eGFR from baseline to 3 months postoperatively. Planned start Mar 2026; status: authorised.
02
Drugs
levothyroxine sodium
03
Conditions
hypothyroidismchronic kidney disease (CKD)nephropathy
Beyond the preview
Go deeper on 2025-524175-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524175-23-00.